Participate in a Clinical Trial

This is a Phase 2/3 10-week study to evaluate the effects of AXS-05 in the treatment of agitation in patients with Alzheimer’s disease.’.

Who can be involved:

• Male or female, aged 65 – 90 years
• Must have clinically significant agitation. This may include physical aggression, verbal aggression or excessive motor activity (such as pacing or rocking)
• Diagnosed with probable Alzheimer’s disease
• Has an identified, reliable, study partner
• If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 2 months prior to commencing the study

For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or email aarfctd@alzheimers.com.au

This study will evaluate the effect of gantenerumab (RO4909832) on cognition and functioning and the safety and pharmacokinetics in participants with prodromal Alzheimer’s Disease.

Who can be involved:

• Male or female, aged 50 to 90 years
• Has an identified, reliable, study partner (who spends 10+ hours a week with the subject)
• Must have mild cognitive impairment due to Alzheimer’s disease or diagnosed with Alzheimer’s dementia

For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au

To test whether two investigational drugs called CAD106 and CNP250, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer’s disease in participants at risk to develop clinical symptoms based on their age and genotype.

Who can be involved:

• Male or female, aged 60 to 75 years
• Does not have a current medical or neurological condition that might impact cognition or performance on cognitive assessments
• Has an identified, reliable, study partner

For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au

This is a Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and function after 48 weeks of daily treatment. To assess the safety and efficacy of ANAVEX2-73 for the treatment of early Alzheimer’s disease.

Who can be involved:

• Male or female, aged 60 – 85 years
• Must be diagnosed with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease
• Has an identified, reliable, study partner
• If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months prior to screening

For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au

A Phase 2 study assessing the safety impact of continuing dosing aducanumab in asymptomatic amyloid-related imaging abnormalities in participants with mild cognitive impairment due to Alzheimer’s disease or with mild Alzheimer’s disease.

Who can be involved:

• Male or female, aged 50 – 85 years
• Must be diagnosed with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease
• Has an identified, reliable, study partner
• If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months prior to screening

For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au

This study aims to evaluate the impact of testosterone alone or in combination with fish oil on amyloid load in the brain, as well as whether it affects performance on tests of memory, cognition and function.

Who can be involved:

• Males aged 60 to 80 years
• Have memory concerns
• Does not have a current medical or neurological condition
• Not currently taking testosterone or diagnosed with hypogonadism
• Western Australia and New South Wales residents

For further information please contact

WA Contact: Shane Fernandez, Study Coordinator on Ph: 08 6304 3957 or Email: s.fernandez@ecu.edu.au

NSW Contact: Deepal Wakade, Clinical Trial Coordinator on Ph: 02 9812 2974 or Email: deepal.wakade@mq.edu.au